drugset / Trial / NCT01993433

A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis

NCT01993433 ↗

Phase 2 Completed 23 enrolled Dermira, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of plaque psoriasis when applied twice daily for 6 weeks.

Timeline

Start
2013-10
Primary completion
2014-02
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject DRM02 Unknown 0.25 % Topical

Indications